KKR & Co. (KKR)
(Real Time Quote from BATS)
$97.47 USD
+3.00 (3.18%)
Updated Apr 23, 2024 12:48 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KKR 97.47 +3.00(3.18%)
Will KKR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KKR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KKR
KKR & Co. Inc. (KKR) Rises Higher Than Market: Key Facts
KKR & Co. Inc. (KKR) Dips More Than Broader Market: What You Should Know
KKR: What are Zacks experts saying now?
Zacks Private Portfolio Services
KKR & Co. Inc. (KKR) Stock Slides as Market Rises: Facts to Know Before You Trade
The Zacks Analyst Blog Highlights SEI Investments, Artisan Partners, KKR, T. Rowe and Affiliated Managers
Top 5 Investment Management Stocks to Enrich Your Portfolio
Other News for KKR
Insider, Politico Owner Could Have Eyes On Wall Street Journal Next: Why Battle With Bill Ackman Is Far From Over
KKR to acquire Immedica Pharma, terms undisclosed
KKR to acquire Swedish pharma firm Immedica
KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
Weekly Commentary: World-Wide De-Risking/Deleveraging